Q3 Earnings Forecast for TARS Issued By William Blair

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – William Blair issued their Q3 2025 earnings per share (EPS) estimates for Tarsus Pharmaceuticals in a research report issued on Wednesday, August 6th. William Blair analyst L. Hanbury-Brown expects that the company will earn ($0.38) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($1.46) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.40 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $1.39 EPS.

TARS has been the topic of several other research reports. HC Wainwright raised Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 target price on the stock in a research note on Tuesday, May 27th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a research note on Monday, May 5th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Guggenheim upped their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Up 4.6%

NASDAQ:TARS opened at $50.07 on Monday. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -21.49 and a beta of 0.79. Tarsus Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $57.28. The company has a current ratio of 5.26, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22. The business’s fifty day moving average price is $41.67 and its 200 day moving average price is $45.67.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The company had revenue of $102.66 million for the quarter, compared to analysts’ expectations of $95.81 million.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $44,000. Amalgamated Bank increased its holdings in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after acquiring an additional 295 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after acquiring an additional 339 shares during the last quarter. Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. Finally, AlphaQuest LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter valued at about $189,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.